A review of the infection-associated cancers in North African countries by Wafaa Mohamed Hussein et al.
REVIEW Open Access
A review of the infection-associated
cancers in North African countries
Wafaa Mohamed Hussein1, Wagida A. Anwar1, Mohammed Attaleb2, Loubna Mazini3, Asta Försti4,5,
Roxana-Delia Trimbitas3 and Meriem Khyatti3*
Abstract
Cancer is typically classified as a leading non-communicable disease; however, infectious agents, such as Helicobacter
pylori (H. pylori), hepatitis B virus (HBV), hepatitis C virus (HCV) and human papilloma virus (HPV), contribute significantly
to the pathogenesis of various cancers. Less developed countries, including countries of the North African (NA) region,
endure the highest burden of infection-related cancers. The five most common infection-associated cancers in NA in
order of incidence are bladder cancer, cervical cancer, liver cancer, stomach cancer, and nasopharyngeal carcinoma. This
review aims to outline the epidemiologic pattern of infection-associated cancers in five NA countries (namely: Morocco,
Algeria, Tunisia, Libya and Egypt) highlighting the similarities and differences across the region. The present study
employed an initial literature review of peer-reviewed articles selected from PubMed, ScienceDirect and World Health
Organization (WHO) databases based on key word searches without restriction on publication dates. Original research
articles and reports written in French, as well as data from institutional reports and regional meeting abstracts were also
included in this extensive review. Egypt, Libya, Tunisia, Algeria and Morocco were selected to be the focus of this review.
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Background
Cancer is typically classified as a non-communicable
disease; however, infectious agents contribute signifi-
cantly to cancer etiology [1]. The International Agency
for Research on Cancer (IARC) has labelled some infec-
tious agents as carcinogens, these include; Helicobacter
pylori (H. pylori), hepatitis B virus (HBV), hepatitis C
virus (HCV), Opisthorchis viverrini, Clonorchis sinensis,
human papillomavirus (HPV), Epstein-Barr virus (EBV),
human T-cell lymphotropic virus type 1 (HTLV-1), hu-
man herpes virus type 8 (HHV-8, also known as Kaposi’s
sarcoma herpes virus; KSHV) and Schistosoma haemato-
bium (S. haematobium) [2]. The data consistently point
to an association between an infectious agent and a spe-
cific malignancy and ranges from 100 % (e.g. cervical
cancer (CC) attributable to HPV) to 0.4 % (liver cancer
caused by liver flukes), depending on the infectious
agent, the cancer and the geographical location [3]. Per-
sistent infection with certain types of HPV has been
established as a necessary cause for CC, accounting for
100 % of these tumors. In addition to CC, oncogenic
HPVs were found in approximately 88 % of anal cancers,
70 % of vaginal cancers, 50 % of penile cancers, and
43 % of vulvar cancers. Among other cancer types,
HHV-8 has been found in nearly all tumors in patients
with Kaposi’s sarcoma (KS). In endemic areas, all squa-
mous cell carcinomas (SCCs) are assumed be attributed
to schistosomiasis. H. pylori infection is consistently as-
sociated with gastric carcinoma and all nasopharyngeal
carcinoma (NPC) cases are associated with EBV infec-
tion, while T-cell leukemia is rare in HTLV-1 negative
subjects. Overall, 75 % to 80 % of cases of primary liver
cancers are attributable to persistent infections with
either HBV (50–55 %) or HCV (25–30 %) [1].
Malignant transformations of human cells that may be
caused by infectious agents occur through different mech-
anisms of action [4]. These agents may act as direct car-
cinogens through the expression of oncogenes. The
resulting onco-proteins can interact with cellular proteins
leading to disruption of cell-cycle check-points, inhibition
of apoptosis, and enhancement of cell immortalization. In-
fectious agents, such as HPV, HBV, HTLV-1, EBV and
KSHV, act through this mechanism. Another mechanism
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of malignant transformation occurs as follows: chronic in-
fection followed by chronic inflammation leads to the re-
lease of inflammatory mediators and the production of
free oxygen radicals, which have direct mutagenic effects
in addition to promoting tumor neo-vascularization and
survival. Inflammation-induced cancers are associated
with HCV, H. pylori and S. haematobium. Immune-
suppression induced by human immunodeficiency virus
(HIV-1), as well as KSHV and EBV, strongly increases the
incidence of many other infection-associated cancers.
A systematic analysis by de Martel et al. from 2012 es-
timated that 16.1 % (about 2 million) of all new cancer
cases reported during 2008, were directly attributable to
infections; the majority of which (80 %, 1.6 million) orig-
inated in less developed countries. The proportion of
infection-associated cancers ranged between 7.4 % and
22.9 % in developed and developing countries, respect-
ively. According to the same study, in North African
(NA) region the proportion was estimated at 12.7 %,
with local variations between and within countries [1, 5].
Hepatitis B and C, HPV, and H. Pylori have been asso-
ciated with about 95 % of infection-associated cancer
cases. Cancer sites affected include cancers of the liver,
cervix, selected head and neck cancers, and gastric can-
cers. These viruses differ in their contribution to cancer
burden worldwide. HPV contributes equally to the can-
cer burden in both developed and developing countries.
H. Pylori results in more cancer cases in developed
countries, while HCV and HBV result in higher cancer
rates in developing countries [6]. In NA, the five most
common infection-related cancers in descending order
are: bladder cancer, cervical cancer, liver cancer, stomach
cancer, and NPC (Table 1). This review aims to demon-
strate the influence of infectious agents on cancer
pattern in NA countries and to summarize and provide
up-to-date data in a region-specific manner.
Methods
The present study employed an initial literature review
of peer-reviewed articles published in PubMed, Science-
Direct, and World Health Organization (WHO) data-
bases with no restriction on publication date. Original
research articles and reports written in French, as well
as data from institutional reports and regional meeting
abstracts were also included in this extensive review. In
the articles and reports, data in the NA countries (Egypt,
Libya, Tunisia, Algeria and Morocco) were considered
eligible when the nature of epidemiological data, such as
prevalence and incidence rates, were specified. Combi-
nations of keywords used in the searches were: infectious
agents (EBV, HCV, HBV, schistosomiasis, HPV, H. Pylori,
HHV-8 and HTLV-1); country name (Egypt, Algeria,
Morocco, Tunisia, Libya, NA and Maghreb); cancer type
(bladder, cervical, liver, hepatocellular carcinoma (HCC),
anogenital, and NPC).
Schistosomiasis and bladder cancer
Bladder cancer is the 11th most common cancer world-
wide, affecting predominantly men (77 %), with an
estimated 429,793 new cases in 2012 and 165,068 deaths
in the same year [7, 8]. Egypt has the highest age-
standardized incidence rate (ASR) of bladder cancer in
men in NA (21.8/100,000 persons per year), followed by
Algeria and Morocco (15.3/100,000 persons per year)
and Libya and Tunisia (10.8/100,000 persons per year)
(Fig. 1). Egyptian men also have the highest age stan-
dardized mortality rate in the world (11.1 per 100,000
men), which is twice the rate in Europe (5.2/100,000)
and three times that in the United States (4.0/100,000)
[7]. Consistent with the worldwide data, cases in men
comprise a higher fraction of bladder cancer as com-
pared to women in NA (Fig. 1). This observation is likely
due to the high prevalence of urinary schistosomiasis,
and the high rate of smoking among men [9].
In the 1920s S. haematobium infection rates in Egypt
were as high as 70–80 %. As a direct result of several
control strategies that have been implemented through-
out the country for the last two decades, Egypt has re-
cently reached low schistosomiasis endemicity [10]. The
prevalence of schistosomiasis dropped to 6.6 % in 1993
and then to 1.9 % in 2002 and 1.2 % in 2006 [11, 12].
Schistosomiasis is mostly eliminated in both Tunisia and
Morocco, as no new cases were reported in these coun-
tries since 1984 and 2004, respectively [13]. The Moroc-
can schistosomiasis elimination strategy started in 1994
and disease transmission was curtailed by 2009 based on
Table 1 Total cancer incidence per 100,000 of most common infection-associated cancers in North African countriesa: Globocan, 2012 [7]
Morocco Algeria Tunisia Libya Egypt
Bladder (Schistosoma haematobium) 5.8 5.9 8.3 8.6 13.1
Cervix uteri (HPV) 14.3 8.5 4.8 9.7 2.3
Liver (HCV and HBV) 1.2 1.5 1.1 4.8 25.5
Stomach (Helicobacter pylori) 4.0 6.0 4.2 3.7 2.5
Nasopharyngeal (EBV) 2.3 3.2 2.3 231 0.3
aTotal cancer incidence (not only the incidence attributed to infectious agents)
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the absence of serum antibodies, indicating undetectable
or complete absence of transmission, in a sample of
2,382 children selected from provinces with a history of
high incidence [14]. In Libya, S. haematobium is en-
demic in some limited regions (near the Mediterranean
coast, in the central part and near the southwestern
border of Algeria). The estimated prevalence of Schisto-
soma in Libya between 2003 and 2010 was 5 %. In
Algeria, S. haematobium is absent in most parts of the
country and the risk of infection is localized in the prov-
ince of Boumerdes [15].
Regarding bladder cancer incidence, the Algerian can-
cer registry, Setif, reported an increased trend in bladder
cancer during a study period of 25 years (from 1986 to
2010). Bladder cancer rates (per 100,000) increased in
men from 1.6 in 1986–1990 to 10.3 in 2006–2010 [16].
Similarly, in Morocco, based on the Casablanca cancer
population registry, the ASR of bladder cancer increased
in men from 5.8 in 2004 to 10.2 in 2007 [17]. Different
trends were observed in the other NA countries, with ei-
ther a stabilized or a decreasing tendency. The incidence
rates remained stable over time in Tunisia (1993–2006)
[18]. Bladder cancer ASR decreased from 11.7 in 2003 to
3.2 in 2012 among men in Libya [19]. In Egypt, the rela-
tive frequency of bladder cancer dropped from 27.6 % in
1970 to 11.7 % in 2007, which correlates well with a de-
crease of Schistosoma association from 82.4 % to 55.3 %
during the same study period. A significant rise of
tobacco-associated transitional cell carcinoma (TCC) from
16 % to 65.8 % and a decrease in SCC from 75.9 % to
28.4 % was however reported for the same period [20].
Shistosomiasis-associated bladder cancer presents a
distinctive clinicopathologic profile, different from that
reported from the Western countries. In contrast to the
Western countries, which predominantly exhibit TCC as
the major form of bladder cancer (estimated at 90–
95 %), Egypt has reported as much as 75 % of their cases
as SCC in the past [9, 21, 22]. Between 1970 and 1974,
26.7 % of patients registered in the National Cancer In-
stitute (NCI) at Cairo University suffered from bladder
cancer attributed to schistosomiasis [21]. Another study
of 2778 patients at the NCI, showed that bladder cancer
patients in 2005 had a six fold increased risk of TCC vs.
SCC compared with patients treated in 1980 [23]. Thus,
despite the considerable elimination of S. haematobium-
related infections and hence the resulting bladder cancer,
the effect of that had been impeded by tobacco-related
bladder cancer among Egyptian men.
Human Papilloma virus and cervical cancer
Cervical cancer is the world’s third most common can-
cer among women, with an ASR of 14 per 100,000
women. The main bulk of CC cases occur in developing
countries (85 %), yet NA countries show an overall low
Fig. 1 Estimated age standardized incidence for bladder cancer in North African Countries: Globocan, 2012 [7]. Estimated age standardized
incidence for bladder cancer in five North African Countries according to GLOBOCAN 2012 report shows that Egypt has the highest burden of
bladder cancer
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incidence (ASR: 6.6 per 100,000). Despite the relatively
low incidence rates, CC is the second most common
cancer among women in Algeria and Morocco and the
third most common cancer in Tunisia. An increasing
East-West gradient exists, ranging from as low as 2.3/
100,000 women in Egypt to as high as 14.3/100,000
women in Morocco (Fig. 2) [7].
The age specific rates in Algeria and Morocco, were
found to increase rapidly with age until 50–54 or 55–59
years, and then remained constant (Algeria) or decline
(Morocco). Incidence rates reached relatively high values
(almost 60/100,000) in Morocco between the ages of
50–54 years and around 40/100,000 in Algeria for ages
above 55 years. In Egypt, the incidence rate was lower
than 10/100,000 across all age groups. No cases of CC
were observed among women below 30 years of age in
Algeria, Morocco, and Egypt [24].
Almost 100 % of all CC cases are caused by the HPV,
which ranks as the most common sexually transmitted
infection globally [3]. There are more than 150 strains of
HPV with varying carcinogenic potential. HPV-16 and
18 overshadow other strains (31, 33, 35, 45, 52 and 58)
contributing to over 70 % of all CC cases and being re-
sponsible for 41–67 % of high-grade cervical lesions and
16–32 % of low-grade cervical lesions [25–27]. Paucity
of published data in the NA region obscure the true epi-
demiological picture, however it is estimated that HPV
prevalence falls between 5–12 % in low-risk population
groups and 20–49 % in high-risk groups, with an average
of 21.3 % [28]. Data of a meta-analysis also reported that
the crude and adjusted HPV prevalence among women
with normal cytological findings in NA (Egypt, Tunisia,
Morocco and Algeria) were estimated at 10.9 % and
9.2 %, respectively [29]. The average prevalence is
slightly higher in cases of cervical intraepithelial neopla-
sia (CIN) and established CC cases (25–90 % and 61–
98 %, respectively) [28]. Mirroring the global situation,
HPV16 is the most prevalent type among diagnosed can-
cer cases in NA countries (59 %), followed by HPV-18
(8.6–17 %) [30]. According to data available till 2013,
NA countries resemble each other in HPV prevalence,
which hovers around 10.5 %, aside from Tunisia which
has a higher national prevalence (14.6 %), reasons for
which are presently unclear (Table 2) [31].
Human Papilloma virus and other ano-genital cancers
While HPV is the major cause of various types of ano-
genital cancers, such as anal, vulvar, vaginal, and penile
cancers, few studies report this correlation perhaps due
to their low incidence rates, and a focus on CC, respect-
ively. Anal cancer has a low worldwide incidence of 1
per 100,000 in the general population. Interestingly, the
majority of vulvar cases were found in developed na-
tions. Contrary to vulvar cancer, a higher prevalence
Fig. 2 Estimated age standardized incidence and mortality rates for cervical cancer in North African countries: Globocan, 2012 [7]. Estimated age
standardized incidence and mortality rates for cervical cancer in five North African countries according to GLOBOCAN 2012 report shows an
increasing East-West gradient of cervical cancer
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(68 %) of vaginal cancer was observed in developing na-
tions. Equally rare is worldwide incidence of penile can-
cer (22,000 new cases/year), which is highly positively
correlated with CC [32–34]. Low incidences of ano-
genital cancers have been reported across NA coun-
tries. ASRs of ano-genital cancers in NA countries
did not exceed 3.1/100,000 for anal cancers, 0.7 for
vulvar cancer and 0.4 for vaginal cancer (Table 3).
Libya and Morocco do not currently have any official,
published data [35–37].
The only available data on HPV in anogenital cancers
from NA are from a population from west Algeria, report-
ing a prevalence of HPV of 40 % in vaginal cancers, 17 %
in vulvar cancers and 33 % in anal cancers [38].
Viral hepatitis and liver cancer
Globally, liver cancer or HCC is the fifth cancer among
men (7.5 % of all cancers in men) and the ninth among
women (3.4 % of all cancers in women). About 85 % of
cases occur in developing countries with 2.4:1 male to
female ratio [7, 39]. In NA, liver cancer is the most com-
mon cancer in men and the second most common one
among women with an estimated ASR of 18 and 7 per
100,000 men and women, respectively. A large disparity
exists with a decreasing East-West gradient observed
across the region, where incidence in both sexes ranges
from a lowest of 1.1/100,000 in Tunisia to a highest of
25.5/100,000 in Egypt (Fig. 3). In Egypt, the male:female
ratio reaches 3.8:1, probably due to the higher prevalence
of HBV and HCV among men. In addition, the relatively
high rates of NHL in Egypt may be explained, in part, by
the high HCV prevalence in the country [7].
About 5 % of all cancers are thought to be the direct
result of chronic infections with hepatitis viruses [3]. A
strong geographic correlation has been found globally
between the incidence of liver cancer and the prevalence
of hepatitis B surface antigen (HBsAg) or hepatitis C
antibody (anti-HCV) [40–43]. Chronic HCV is impli-
cated in most HCC cases in developed countries and in
one-third of cases in developing countries [44]. In NA
there is a 33-fold increase in HCC with HCV infection
and a 10-fold increase with HBV infection [45]. In
addition, there is evidence for a causative association be-
tween chronic HCV infection and non-Hodgkin lymph-
oma (NHL), although the underlying mechanism is still
not fully understood [46–48].
Hepatitis B
Most NA countries have an intermediate endemicity of
HBV (Table 4) [49]. In Algeria, there is a significant lack
of recent data on the prevalence of HbsAg in the general
population, with the last publication dating back almost
20 years ago. The WHO estimates the prevalence in
Algeria to stand anywhere between 2 % to 7 %, while Khe-
lifa et al. reported it as 2.2 % in North Eastern regions in
1998 with HBV genotype D being the most common there
accounting for 93 % of all HBV infections [50].
The sero-prevalence of HBsAg in the general population
in Libya varies between 1.3 % and 5.8 %. A national sero-
epidemiological study conducted between 2004 and 2005
showed a prevalence of 2.2 % with 120,000–150,000
chronic HBsAg carriers [51]. A study on hemodialysis pa-
tients detected HBsAg prevalence of 2.6 % [52]. A low
prevalence (1.3 %) was found among blood donors. HBV
genotype D is the most prevalent in Libya [53].
Morocco has a low estimated prevalence for chronic
HBV, ranging between 1 % and 3 % [54–58]. The HBsAg
burden in the general population is 1.5 %, which was
similar to that reported among health professionals
(1 %), yet this figure increases to 1.7 % among sexually
active subjects and to 2 % among hemodialysis patients
[54–56, 59]. At Moroccan blood banks, the prevalence
Table 2 HPV prevalence in North African countries among different cell types according to data available till 2013 [31]
Country HPV prevalence in women
with normal cytology
HPV 16 and/or 18 in women with
Normal cytology Low grade lesions High grade lesions Cervical cancer
Egypt 10.5 5.1 18.5 40 78.4
Libya 10.7 5.1 18.5 40 78.4
Tunisia 14.6 5.2 18.5 40 78.4
Algeria 10.5 9 18.5 40 77.1
Morocco 10.5 2.9 20.9 40 79.2
Table 3 Age-standardized incidence rate (ASR) of ano-genital
cancers in North African countries [35–37]
Egypt Tunisia Algeria
Anal cancer 0.4 0.2 Algiers:
Male 3.1; Female 2.5
Setif region:
Male 0.1; Female 0.1
Vulvar cancer 0.7 0.3 Algiers: 0.1
Setif region: 0.0
Vaginal cancer 0.2 0.4 Algiers: 0.1
Setif region:0.2
Penile cancer 0.0 0.0 Algiers : 0.0
Setif region:0.0
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has remarkably decreased between 2000 and 2010 from
2.5–2.8 % to 0.8–1.3 % [57, 59, 60]. HBV genotype D ac-
counts for 90 % of all HBV infections in Morocco [61].
In Tunisia, the estimated HBV prevalence ranges be-
tween 2 % and 7 %, being highest in South and Midwest
regions. A survey on blood donors in 1994 revealed a
prevalence of 5 % [62]. In 2010, the overall prevalence of
HBsAg burden in a population of chronic carriers and of
volunteers was 5.3 % and 2.9 % respectively. A large
study conducted in 1997 found that 6.5 % of the study
group was HBsAg positive [63]. HBV genotype D was
found in 80 % of patients in Tunisia with dominant sub-
genotype D7 [64, 65].
In Egypt, an earlier study reported HBsAg prevalence
between 8 % and 11.7 % [66]. Recently, HBV prevalence
in the general population has been varying from 1.3 % to
6.7 % [49]. Recent blood donor screening revealed a
prevalence of HBsAg of 1.3–1.4 % [67, 68]. However, an-
other cross-sectional study found that 16.6 % of blood
donors were positive for total anti-HBV core antibodies
of which 64 % were positive for HBsAg [69]. The preva-
lence of HBV among Egyptian liver cancer patients was
25.9 % and was shown to decrease over time [70]. HBV
genotype D accounts for an estimated 87 % of the total
infection in Egypt [71].
Hepatitis C
The global HCV prevalence is 2.35 % with estimated 160
million chronically-infected people [72]. It is a major
cause of severe liver disease resulting in 0.35 million an-
nual deaths [73]. HCV infection is a major public health
issue in the NA Maghreb region (Morocco, Mauritania,
Algeria, Tunisia, and Libya), where the prevalence ranges
between 1–2 %. The highest prevalence however is re-
ported in Egypt, ranging from 6 % to 28 % with an average
of 14.7 % [74]. In addition, immigrants from the NA re-
gion to Europe were shown to have a higher prevalence
compared to the general European Union population in
Fig. 3 Estimated age standardized incidence and mortality rates for liver cancer (in both sexes) in North African countries: Globocan, 2012. [7].
Estimated age standardized incidence and mortality rates for liver cancer in five North African countries according to GLOBOCAN 2012 report
shows that Egypt has the highest burden of liver cancer with a decreasing East-West gradient
Table 4 Prevalence of HBV in North African countries according to data available till 2013 [49]
Country HBV prevalence (%) in population HBV prevalence (%) in Hemodialysis patients Most common genotypes Less common genotypes
Egypt 4 4.1 D Subtype D1
Libya 2–7 2.6 [52] D
Tunisia 2–7 No data D A, E
Algeria 3.6 No data D A, E
Morocco 1.3 2 D A
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host countries, raising the issue of national immigrant
screening programs [75–77].
In Algeria, a survey conducted in 1995 among blood
donors and pregnant women, found an HCV prevalence
of 0.2 % [78]. The Algerian Ministry of Health estimated
that the prevalence had reached 2.5 % in 2009 [79]. High
prevalence rates, were found among hemodialysis pa-
tients (25 % to 53 %) and in hemophiliacs (31.6 %) [80].
In Algeria, subtype 1b is the most prevalent genotype
(86.2 %) [81].
In the mid-1990s, the prevalence of HCV cases among
Libyan general population was 8 % and was labeled as
‘community acquired’ [82]. A more recent national sero-
epidemiological survey denoted that the prevalence had
declined to 1.2 % [51]. Prevalence was higher among
renal dialysis (20.5 %) and poly-transfused patients
(11 %), transmission being mainly nosocomial [83].
Genotype 4 was the most common (35.7 %), followed by
genotype 1 (32.6 %) [84].
In Morocco, the estimated prevalence among the general
population and blood donors was 0.3 % and 2 % respect-
ively [85–87]. The highest prevalence rates were observed
in hemodialysis patients (34 %-68 %), hemophiliac patients
(42 %), and intravenous drug users (60.1 %) [85, 88–91]. A
survey conducted in 2001 in Casablanca revealed a 5 %
prevalence of anti-HCV antibodies in traditional barbers.
A more recent study showed a low prevalence among
young army recruits (0.35 %), blood donors (0.33 %), and
hospitalized patients (3.08 %) [60]. The most commonly
found HCV genotypes were 1b (47.6 %), 2a/2c (37.1 %)
and 1a (2.8 %) respectively [92].
In Tunisia, the average prevalence of anti-HCV anti-
bodies is 1.6 % ranging between 0.3 % in the south and
3 % in the northwest region where several reports re-
vealed the presence of a chronic hepatitis C cluster. An
average prevalence of 0.6 % was reported in blood do-
nors. Genotype 1b predominates and the prevalence
ranges from 79 % to 90 % [62, 93–95].
The Egyptian Demographic Health Survey of 2008 esti-
mated the prevalence of anti-HCV antibodies to be
14.7 %; the highest in the world to date. This inflated
prevalence is thought to be associated with the mass par-
enteral anti-schistosomiasis therapy implemented during
the 1950s-1980s [96–98] resulting in a large reservoir of
chronic HCV. Between 2000 and 2007 the annual sero-
prevalence of HCV among blood donors declined from
17.7 % to 7.4 % [67]. However, ongoing endemic transmis-
sion is suggested with an estimated incidence of nearly
6.9/1,000 persons per year [96, 99]. HCV genotype G4 is
the most common genotype in Egypt [98].
A meta-analysis of 32 case-control studies reported
that co-infection with HBV and HCV is strongly associ-
ated with HCC (OR = 165), compared with mono-
infection with HCV (OR =17) or HBV (OR = 23) [100].
Similarly, a recent study in the NA region reported a 33-
fold increase in HCC with HCV infection and a 10-fold
increase with HBV infection [ 45]. This risk increased
84-fold when patients were co-infected by both viruses,
suggesting a synergistic effect between the two infec-
tions, although the exact mechanism has not yet been
established.
A multicenter case-control study conducted between
2002 and 2005 in patients with HCC from Algeria,
Morocco and Tunisia, reported that 60 % of HCC patients
were positive for anti-HCV and 18 % for HBsAg [45]. In
Egypt, there was a significant increase in the annual pro-
portion of patients with HCC among chronic liver disease
patients attending the Cairo liver center, during a study
period ranging from 4.0 % in 1993 to 7.2 % in 2002, with a
significant drop of HBsAg positivity among HCC patients
from 38.6 % to 20.5 % and a slight increase of HCV posi-
tivity from 85.6 % to 87.9 % [101].
The Algerian Cancer Registry in Setif was the only one
that could provide longitudinal data on HCC over a 25-
year period (from 1986 to 2010). The liver cancer rate
was found to increase since 1996–2000 after a decrease
for both sexes (annual percent changes of +8.9 % in men
and +5.4 % in women) [16]. In Libya, no significant
change in liver cancer incidence was observed between
2003 (ASR = 3.3) and 2012 (ASR = 4)) [19].
H. Pylori and stomach cancer
Stomach cancer is the 4th common cancer in men and
the 6th in women worldwide with an ASR of 17.4 and
7.5 per 100,000 respectively. Stomach cancer incidence
is much less in NA (ASR: 4.3 and 2.7 per 100,000 in
men and women, respectively) with an increasing East-
West gradient (Fig. 4) [7].
H. pylori infection is the etiological agent in various
gastric pathologies and the disease severity has been at-
tributed to some H. pylori genotypes [102]. It is esti-
mated that H. pylori infection increases the risk of
stomach cancer by nearly six times. Prevalence rates dif-
fer by age, ethnicity and socioeconomic characteristics,
being higher in developing countries [103].
In Morocco, a 69 % prevalence of H. pylori infection
was found among patients with digestive complaints.
Commonly infected sites were the atrium (73 %), the cor-
pus (21 %) and the pylorus (6 %). The potentially carcino-
genic cagA antigen was detected in 42.3 % of cases [104].
In Egypt, several studies showed high prevalence of infec-
tion in various settings. H. pylori IgG antibodies were de-
tected in 68 % of a group of women with primary
fibromyalgia [105]. H. pylori prevalence of 72.38 % was
found among school children [106]. In Tunisia, 66.7 % of
a group of symptomatic patients were seropositive for H.
pylori compared to 64 % of a group of blood-donors
[107]. The prevalence of H. pylori infection reached
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51.4 % among six-year old children [108]. The estimated
prevalence of H. pylori infection in Algeria was over 70 %
[109]. In 1989, a sero-epidemiological study found that
the prevalence among children in the first decade of life
was 45 % which rose steadily to reach 92 % among those
in the fifth decade [110]. Despite the high infection rates
in NA countries, stomach cancer remains relatively low,
indicating that other determinants such as genetic factors
or virulence of the organism influence the carcinogenic
potential and ultimate cancer development.
Epstein-Barr virus associated cancers
NPC is the 22nd most common cancer worldwide, but it
is the 6th most common cancer in NA. In addition to
NA it is prevalent in Southern China, Southeast Asia,
Japan and the Middle East [111, 112]. EBV is a group I
carcinogen, implicated in NPC, Burkitt’s Lymphoma,
Hodgkin’s, non-Hodgkin’s and T cell lymphoma [113].
EBV infects over 95 % of the global adult population
[114], yet NPC results from an interaction between EBV
infection and environmental/genetic factors [112]. The
highest observed incidence of NPC in NA is in Algeria
(3.2/100,000) and the lowest is in Egypt with 0.3/100,000
(Fig. 5). Interestingly, some typical NA foods seem to be
associated with increased risk of NPC [115, 116]. A
study conducted over 4 years (2002–2005), in Morocco,
Algeria and Tunisia reported that the consumption of
butyric acid (found in rancid butter (smen), rancid sheep
fat, and dried mutton stored in oil (quaddid)) was sig-
nificantly associated with an increased risk of NPC, with
the presence of butyric acid in these traditional foods
acting as a potential EBV activator [116].
HHV8 and Kaposi’s sarcoma
Kaposi’s sarcoma (KS) does not appear in the top 25 can-
cers in the world, however, it is the 10th most common
cancer in Africa, with an ASR of 4.7/100,000 probably due
to the high prevalence of HIV [7]. In Morocco, anti-
HHV8 antibody was found in 92 % of KS cases, mostly af-
fecting males [117, 118]. Kaposi sarcoma was the cause of
death in 6 % of a sample of HIV-positive patients [119].
In Tunisia, the sero-prevalence of HHV8 was 13.8 % in
blood donors, 13 % in pregnant women, and 12 % in chil-
dren [120]. HHV8 was found in 17 % of kidney transplant
patients [121]. Another study noted that 7 % of adult renal
transplant recipients developed various cancers, of which
41.6 % developed KS [122]. Kaposi sarcoma was found in
4.5 % of skin cancer patients registered in southern
Tunisia over a period of 24 years (1979–2002) [123]. In a
small cohort with acquired immunodeficiency syndrome
(AIDS), KS emerged in 22.7 % of cases within 0 to 10 years.
This time frame was similar in the neighboring Morocco
Fig. 4 Estimated age standardized incidence and mortality rates for stomach cancer (in both sexes) in North African countries: Globocan, 2012 [7].
Estimated age standardized incidence and mortality rates for stomach cancer in five North African countries according to GLOBOCAN 2012 report
shows that Algeria has the highest burden of stomach cancer
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[124]. In Egypt, a prospective study on 1–4 year old chil-
dren with febrile syndrome showed that 41.9 % were sero-
positive for HHV-8 [125]. There is a general lack of data
on this subject in Algeria.
HTLV-1 and T-cell Leukemia
There is a close association between T-cell Leukemia
and the presence of antibodies to HTLV-I [126]. How-
ever, few studies have been carried out in the last decade
in Africa and the number of tested individuals is limited.
Sero-positivity for HTLV-I in Morocco is 0.6 %. In
Tunisia, Algeria and Egypt, HTLV-I/II infections were
not observed in blood donors or recipients [127].
Conclusion
Differences in the rates of infection-related cancers across
NA countries are manifested in the high incidence of
bladder and liver cancers and NHL in Egypt versus the re-
markably increasing East-West gradient of CC. Rates of
NPC were also high in all the NA countries except Egypt.
The burden of infection-related cancers is still under-
estimated worldwide and associations with new infec-
tious agents remain yet to be explored. If infectious
diseases associated with cancers were prevented, it is es-
timated that there would be 26.3 % fewer cancer cases in
developing countries and 7.7 % in developed countries.
The administration of the HBV vaccine in addition to the
routine screening of blood and blood products for HBV
and HVC have resulted in a reduced incidence of liver
cancer. Furthermore, HPV vaccines which protect against
HPV-16 & 18 are now available and have the potential to
reduce the incidence of CC. A paradox is the incidence of
SCC of bladder cancer, which markedly decreased in Egypt
as a result of the success of schistosomiasis control, al-
though increased smoking doubtless is a factor contributing
to the increased proportion of TCC bladder cancer in
Egypt. The intermediate prevalence of many communicable
diseases in NA requires a constant epidemiological surveil-
lance and the rapid adoption of available preventative vac-
cines in addition to health education about region-specific
risk factors. Therefore the strategy should shift from a
therapy-based one which is employed after the develop-
ment of a specific malignancy is linked to an infectious
agent to a preventative one based on national vaccination
campaigns, population education on risk factors and other
lifestyle-related preventative measures.
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